Showing 3881-3890 of 7372 results for "".
- Consumer Reports: Many Sunscreens Don't Provide as Much Protection as they Claimhttps://practicaldermatology.com/news/consumer-reports-many-sunscreens-dont-provide-as-much-protection-as-they-claim/2458559/More than 40 percent of sunscreens test well below their advertised sun protection factor (SPF) level, according to Consumer Reports. In the new report, Consumer Reports tested and rated 65 water-resistant lotions, sprays, and sticks with SPF claims of 30 or h
- AAD Survey: Many Use Sunscreen Incorrectlyhttps://practicaldermatology.com/news/aad-survey-many-use-sunscreen-incorrectly/2458561/Many people don’t understand SPF numbers on product labels, and some may not be using sunscreen properly, which could increase their skin cancer risk, the American Academy of Dermatology reports. In a 2016 survey, only 32 percent of respondents knew that an SPF 30 sunscreen do
- Untreated Sleep Apnea Linked to Melanoma Aggressionhttps://practicaldermatology.com/news/untreated-sleep-apnea-linked-to-melanoma-aggressiveness/2458564/Untreated severe obstructive sleep apnea (OSA) is linked to increased aggressiveness of malignant cutaneous melanoma, according to research presented at the American Thoracic Society 2016 International Conference in San Francisco. The study involved 412 patients, average age 55.8, w
- Dermira's Novel Facial Acne Treatment Passes Muster in Phase 2b Studyhttps://practicaldermatology.com/news/dermiras-drm01-performs-well-in-facial-acne-study/2458571/Dermira’s novel topical sebum inhibitor -- DRMO1 -- may put the brakes on facial acne, according to topline results from a Phase 2b dose-ranging study that is paving the way toward a Phase 3 Clinical Program. DRM01 is a novel, small molecul
- ASDS: Skin Cancer Treatments Among Most Frequently Performed Procedures in 2015https://practicaldermatology.com/news/asds-skin-cancer-treatments-among-most-frequently-performed-procedures-in-2015/2458576/Dermatologic surgeons performed nearly 10 million medical and cosmetic procedures in 2015 – up 5 percent since 2014 and 27 percent since 2012, according to the 2015 American Society for Dermatologic Surgery (ASDS) Survey on
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app 
- Mission Pharmacal's Lycelle Head Lice Removal Kit Now Available In Pharmacieshttps://practicaldermatology.com/news/mission-pharmacals-lycelle-head-lice-removal-kit-now-available-in-pharmacies/2458578/Mission Pharmacal's former prescription Lycelle Head Lice Removal Kit will now be available without a prescription. Lycelle is a treatment for the elimination of head lice and their eggs. Lycelle uses a non-pesticidal formulation that is safe for use with children as young as two years o
- Global Derm Market Set to Soar Through 2022https://practicaldermatology.com/news/global-derm-market-set-to-soar-through-2022/2458579/The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%,
- Sienna Biopharmaceuticals Completes $34 Million Series A Financinghttps://practicaldermatology.com/news/sienna-biopharmaceuticals-completes-34-million-series-a-financing/2458586/Sienna Biopharmaceuticals, Inc., a development stage company focused on aesthetics and medical dermatology, completed a $34 million Series A financing led by ARCH Venture Partners. Additional investors included Altitude Life Science Ventures, Partner Fund Management, and Venvest Capital, as well
- Vitiligo and Gray Hair Treatment Breakthrough? Study IDs Mechanism That Controls Skin and Hair Colorhttps://practicaldermatology.com/news/vitiligo-and-gray-hair-treatment-breakthrough-study-ids-mechanism-that-controls-skin-and-hair-color/2458587/A pair of molecular signals controls skin and hair color in mice and humans - and could be targeted by new drugs to treat skin pigment disorders like vitiligo, according to a report out of NYU Langone Medical Center in New York City. Finding ways to activate these pathways could lea